Wednesday, August 10, 2022 6:29:46 AM
BioXcel focused on the launch progress of Igalmi in the Co's 2Q22 update.
Co to focus on US growth4 Igalmi label expansion
The Co plans to expand Igalmi label in2 at-home setting along w other indications such as AD/MDD.
https://twitter.com/Quantumup1/status/1557113642692272130/photo/1
lowered revenue estimated from 17.4 to 3.5m for 2022
Recent BTAI News
- BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 04/25/2024 11:00:00 AM
- BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 04/24/2024 02:30:24 PM
- BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential • GlobeNewswire Inc. • 04/22/2024 11:00:00 AM
- BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia • GlobeNewswire Inc. • 04/10/2024 11:00:00 AM
- BioXcel Therapeutics Announces $25 Million Registered Direct Offering • GlobeNewswire Inc. • 03/25/2024 11:00:00 AM
- BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine • GlobeNewswire Inc. • 03/15/2024 11:00:00 AM
- BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 • GlobeNewswire Inc. • 03/12/2024 11:00:00 AM
- BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 • GlobeNewswire Inc. • 03/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 12:00:49 PM
- BioXcel Therapeutics Announces Termination of Proposed Public Offering • GlobeNewswire Inc. • 02/13/2024 02:00:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 05:45:31 PM
- BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) • GlobeNewswire Inc. • 02/12/2024 12:14:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 10:27:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:53:19 PM
- BioXcel Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 02/08/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 12:08:28 PM
- BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA® • GlobeNewswire Inc. • 02/06/2024 12:00:00 PM
- BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine • GlobeNewswire Inc. • 02/05/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/23/2024 05:15:24 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:16:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 09:57:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 09:55:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 09:54:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 12:22:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 12:00:20 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM